LikeShareFollow
Ribomic Inc. is a clinical stage pharmaceutical company dedicated to advancing aptamer therapeutics, with a particular focus on rare diseases and ophthalmology. Its lead candidate, RBM-007, is in Phas
e 2a for achondroplasia, and has also completed Phase 1/2a for wet AMD.
